3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Uterine Cervical Dysplasia
1
Squamous Intraepithelial Lesions
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Liver Diseases
1
Liposarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
atezolizumab
2
Sorafenib
2
Bevacizumab
2
titanium silicide
1
ledipasvir, sofosbuvir drug combination
1
halofantrine
1
genexol-PM
1
durvalumab
1
avatrombopag
1
aumolertinib
1
Sunitinib
1
Ramucirumab
1
Neoadjuvant Therapy
1
N-monoacetylcystine
1
Leucovorin
1
Injections
1
Immunotherapy
1
Formyltetrahydrofolates
1
Everolimus
1
Cisplatin
1
Catheter Ablation
1
Adjuvants, Pharmaceutic
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liver Diseases
×
Adjuvants, Pharmaceutic
×
Clear all
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled